LLY•benzinga•
Popular Weight Loss Drug Wegovy Shows Encouraging Results in Liver Fibrosis Trial
Summary
Novo Nordisk's ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 1, 2024 by benzinga